Received Mar 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | UNK | Unknown | PO / MO |
Patient took Vivotif once a day, instead of every other day; Case reference number US-BN-2024-000221 is a spontaneous case report initially received from a health care professional via Med Communications (reference number: USBAV24-0378) on 23-Feb-2024 and concerns a patient of unspecified age and gender. The patient's relevant medical history and concomitant medications were not provided. On unspecified dates, the patient took doses of Vivotif (batch number: unknown), at unknown doses, orally, for typhoid immunization. The patient took Vivotif once a day, instead of every other day (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine. No further information was provided.; Reporter's Comments: A patient of unspecified age and gender took doses of Vivotif, at unknown doses, orally, for typhoid immunization. The patient took Vivotif once a day, instead of every other day, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A patient of unspecified age and gender took doses of Vivotif, at unknown doses, orally, for typhoid immunization. The patient took Vivotif once a day, instead of every other day, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.